Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Szkandera, J.
Keeping up the 'race pace' in a patient with nonuterine leiomyosarcoma
FUTURE ONCOL. 2022; Doi: 10.2217/fon-2022-0636 (- Case Report)
Web of Science PubMed FullText FullText_MUG

 

Leading authors Med Uni Graz

Szkandera Joanna

Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:

Tweetable abstract Keeping up the 'race pace' in a patient with nonuterine leiomyosarcoma. The most common site of involvement of leiomyosarcoma is the retroperitoneum, accounting for approximately 50% of all cases. The case study presented herein describes the journey of a man with a grade 2 retroperitoneal leiomyosarcoma at the time of diagnosis. The patient received first-line doxorubicin (six cycles) and evofosfamide (11 cycles) during participation in the phase III, randomized, double-blind SARC021 trial and achieved stable disease. Upon progression, he received 24 cycles of second-line trabectedin with stable disease, then third-line pazopanib for 14 months with stable disease. Finally, he received fourth-line gemcitabine monotherapy for 5 months until disease progression, which was followed by death. Notably, trabectedin provided long-term disease control and maintained the patient's functional performance throughout treatment.

Find related publications in this database (Keywords)

disease control

evofosfamide

retroperitoneal leiomyosarcoma

trabectedin

treatment sequence

© Med Uni Graz • Imprint